CJC-1295
CJC-1295 is a synthetic growth hormone releasing hormone analogue that increases growth hormone and IGF-1 levels. Small early human studies documented that hormonal effect, but it is not approved for human use and there is no adequate trial evidence that it improves body composition, sleep, recovery or aging outcomes.
An evidence-first look at CJC-1295, a growth hormone releasing hormone analogue sold online: what studies exist, its unapproved status, risks and unknowns.
It raises growth hormone. That is the beginning of the question, not the answer.
Key takeaways
- Raising growth hormone is a measurable effect, not a clinical benefit.
- Human data is limited to small early studies of hormone levels and safety.
- Not approved for human use; prohibited in sport.
- Growth hormone axis stimulation carries recognised metabolic risks.
Measurable hormone change is not the same as benefit
Studies confirming that CJC-1295 raises growth hormone and IGF-1 are frequently cited as though they show it works. They show the mechanism operates. Whether that produces better body composition, sleep or recovery in a healthy adult has not been demonstrated in adequate trials.
The growth hormone assumption
The reasoning behind these products is that growth hormone declines with age, so restoring it should reverse age-related change. Animal longevity research complicates that story considerably, with reduced growth hormone signalling associated with longer life in several models.
Risk and supply
Sustained IGF-1 elevation without monitoring, glucose effects, and an unregulated supply chain together define the practical risk profile.
Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.
Frequently asked questions
Is CJC-1295 the same as growth hormone?
No. It stimulates the pituitary to release the body's own growth hormone rather than supplying it directly.
Does it improve sleep?
That claim is inferred from growth hormone being released during deep sleep. Human sleep-outcome data for this compound is very limited.
Is it approved anywhere?
It is not an approved human medicine in the United States. Tesamorelin is the approved GHRH analogue, for a narrow indication.
Related on Beiing
- Ipamorelin - The other commonly marketed growth hormone peptide.
- Tesamorelin - An approved GHRH analogue for comparison.
- How Beiing rates peptide evidence - The five evidence levels used in this section.
- Peptides & Human Biology - The hub for every page in this section.
Sources
- PubMed - National Library of Medicine - NIH
- FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
- ClinicalTrials.gov - U.S. National Library of Medicine
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.